RU2015137815A - Биодеградируемые и клинически совместимые наночастицы в качестве носителей для доставки лекарственного средства - Google Patents

Биодеградируемые и клинически совместимые наночастицы в качестве носителей для доставки лекарственного средства Download PDF

Info

Publication number
RU2015137815A
RU2015137815A RU2015137815A RU2015137815A RU2015137815A RU 2015137815 A RU2015137815 A RU 2015137815A RU 2015137815 A RU2015137815 A RU 2015137815A RU 2015137815 A RU2015137815 A RU 2015137815A RU 2015137815 A RU2015137815 A RU 2015137815A
Authority
RU
Russia
Prior art keywords
nanoparticle
core
peptide
protein
group
Prior art date
Application number
RU2015137815A
Other languages
English (en)
Russian (ru)
Other versions
RU2015137815A3 (enExample
Inventor
Чиан Дж. ЛИ
Ючжи ЛИ
Кейур ГАДА
Вайбхав САКСЕНА
Сяошу ДАЙ
Джозеф ПРАТА
Намита ДОДВАДКАР
Original Assignee
1ГЛОУБ ХЕЛТ ИНСТИТЬЮТ ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1ГЛОУБ ХЕЛТ ИНСТИТЬЮТ ЭлЭлСи filed Critical 1ГЛОУБ ХЕЛТ ИНСТИТЬЮТ ЭлЭлСи
Publication of RU2015137815A publication Critical patent/RU2015137815A/ru
Publication of RU2015137815A3 publication Critical patent/RU2015137815A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ceramic Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2015137815A 2013-02-05 2014-02-05 Биодеградируемые и клинически совместимые наночастицы в качестве носителей для доставки лекарственного средства RU2015137815A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361761012P 2013-02-05 2013-02-05
US61/761,012 2013-02-05
PCT/US2014/014751 WO2014123935A1 (en) 2013-02-05 2014-02-05 Biodegradable and clinically-compatible nanop articles as drug delivery carriers

Publications (2)

Publication Number Publication Date
RU2015137815A true RU2015137815A (ru) 2017-03-13
RU2015137815A3 RU2015137815A3 (enExample) 2018-01-30

Family

ID=51300093

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015137815A RU2015137815A (ru) 2013-02-05 2014-02-05 Биодеградируемые и клинически совместимые наночастицы в качестве носителей для доставки лекарственного средства

Country Status (13)

Country Link
US (2) US11001840B2 (enExample)
EP (2) EP3845248A1 (enExample)
JP (1) JP6507102B2 (enExample)
KR (1) KR20150132131A (enExample)
AU (2) AU2014215421A1 (enExample)
CA (1) CA2899155A1 (enExample)
ES (1) ES2873600T3 (enExample)
IL (1) IL240148A0 (enExample)
MX (1) MX2015010083A (enExample)
RU (1) RU2015137815A (enExample)
SG (2) SG11201506116XA (enExample)
WO (1) WO2014123935A1 (enExample)
ZA (1) ZA201506530B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2873600T3 (es) 2013-02-05 2021-11-03 1Globe Health Inst Llc Nanopartículas biodegradables y clínicamente compatibles como vehículos de suministro de fármacos.
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3183007B1 (en) 2014-08-19 2020-06-17 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3247796A4 (en) * 2015-01-14 2018-07-11 Exicure, Inc. Nucleic acid nanostructures with core motifs
CA3023451A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US10800817B2 (en) * 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
PL3568122T3 (pl) * 2017-01-10 2024-03-18 Dukebox Sp. Z O.O. Sposób wytwarzania zawiesiny nanocząsteczek soli potasowej albo soli magnezowej
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
KR102120482B1 (ko) * 2018-10-05 2020-06-08 씨제이제일제당 (주) 생분해성 고분자 나노입자를 포함하는 메모리 소자 및 이의 제조방법
EP3996751A1 (en) * 2019-07-12 2022-05-18 The Board Of Trustees Of The Leland Stanford Junior University Functionalized nanoparticles and their use in treating bacterial infections
US20240050369A1 (en) * 2019-10-04 2024-02-15 The University Of Chicago Targeted Nanomedicine for Treating Vascular Disorders
WO2021158476A1 (en) * 2020-02-03 2021-08-12 Rutgers, The State University Of New Jersey Microrna-7 compositions for promoting functional recovery following spinal cord injury and methods of use thereof
US11998615B2 (en) 2021-04-14 2024-06-04 The Board Of Trustees Of The Leland Stanford Junior University Functionalized nanoparticles and their use in treating bacterial infections
CN120714059A (zh) * 2025-05-28 2025-09-30 首都医科大学附属北京安贞医院 一种多羟基核酸药物共递送系统及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219577A (en) 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5879715A (en) * 1997-09-02 1999-03-09 Ceramem Corporation Process and system for production of inorganic nanoparticles
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
DE19912502A1 (de) 1999-03-19 2000-09-21 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung
EP1328254B1 (en) 2000-10-25 2007-02-21 The University Of British Columbia Lipid formulations for target delivery
IN192520B (enExample) * 2001-08-01 2004-04-24 Univ Delhi
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
EP1720520B1 (en) 2004-02-13 2010-06-09 Nod Pharmaceuticals, Inc. Particles comprising a core of calcium phosphate nanoparticles, a biomolecule and a bile acid, methods of manufacturing, therapeutic use thereof
US7611690B2 (en) * 2005-01-04 2009-11-03 Gp Medical, Inc. Nanoparticles for protein drug delivery
WO2007000939A1 (ja) 2005-06-28 2007-01-04 St. Marianna University, School Of Medicine 局所炎症治療用薬剤
CN100435784C (zh) 2005-07-25 2008-11-26 管晓虹 含有和包封中药成分的无机盐纳米粒子的制备方法
WO2008045806A2 (en) * 2006-10-06 2008-04-17 Microislet, Inc. Multilayered polyelectrolyte-based capsules for cell encapsulation and delivery of therapeutic compositions
CN101686939B (zh) 2007-04-17 2013-03-27 巴克斯特国际公司 用于肺部投送的核酸微粒
EP2164475A2 (en) * 2007-07-16 2010-03-24 NorthEastern University Therapeutic stable nanoparticles
EP3121281B1 (en) * 2007-08-27 2021-03-31 1Globe Health Institute LLC Compositions of asymmetric interfering rna and uses thereof
WO2009042625A1 (en) 2007-09-25 2009-04-02 Idexx Laboratories, Inc. Pharmaceutical compositions for administering oligonucleotides
EP2241314B1 (en) 2007-12-14 2013-04-17 Ezaki Glico Co., Ltd. Alpha-lipoic acid nanoparticle and method for producing the same
US20110038941A1 (en) 2007-12-27 2011-02-17 The Ohio State University Research Foundation Lipid Nanoparticle Compositions and Methods of Making and Using the Same
WO2009140421A2 (en) 2008-05-13 2009-11-19 University Of Washington Polymeric carrier
JP2012509904A (ja) 2008-11-26 2012-04-26 ユニバーシティ・オブ・カンザス 核酸送達組成物および核酸送達法
EP2198885B1 (en) 2008-12-19 2012-02-08 Biolitec AG Calcium phosphate nanoparticles as dye carrier for photodynamic therapy
WO2011017297A2 (en) * 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
JP2013504337A (ja) * 2009-09-14 2013-02-07 ナノハイブリッド カンパニー リミテッド 標的特異的siRNA−層状無機水酸化物ナノハイブリッド、その製造方法、及びナノハイブリッドを含有する腫瘍治療用の医薬組成物
JP5491119B2 (ja) * 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
WO2011140024A2 (en) * 2010-05-03 2011-11-10 University Of Utah Research Foundation Nanoparticles produced from recombinant polymers and methods of making and using the same
WO2013040295A2 (en) 2011-09-14 2013-03-21 University Of South Florida Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation
CA2853689C (en) 2011-11-04 2020-06-30 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US20130243699A1 (en) 2011-12-07 2013-09-19 Regents Of The University Of Minnesota Biodegradable Magnetic Nanoparticles and Related Methods
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
ES2873600T3 (es) 2013-02-05 2021-11-03 1Globe Health Inst Llc Nanopartículas biodegradables y clínicamente compatibles como vehículos de suministro de fármacos.

Also Published As

Publication number Publication date
CA2899155A1 (en) 2014-08-14
HK1217906A1 (en) 2017-01-27
JP2016513090A (ja) 2016-05-12
JP6507102B2 (ja) 2019-04-24
MX2015010083A (es) 2016-04-26
EP2953646A1 (en) 2015-12-16
ZA201506530B (en) 2018-11-28
AU2014215421A1 (en) 2015-08-13
US20160046936A1 (en) 2016-02-18
WO2014123935A1 (en) 2014-08-14
KR20150132131A (ko) 2015-11-25
EP2953646B1 (en) 2021-03-10
SG11201506116XA (en) 2015-09-29
SG10201706968UA (en) 2017-09-28
US11001840B2 (en) 2021-05-11
IL240148A0 (en) 2015-09-24
AU2018200903A1 (en) 2018-02-22
US20210230595A1 (en) 2021-07-29
ES2873600T3 (es) 2021-11-03
EP2953646A4 (en) 2017-02-15
WO2014123935A9 (en) 2014-10-23
EP3845248A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
JP2016513090A5 (enExample)
Pan et al. Nanoparticles: promising tools for the treatment and prevention of myocardial infarction
CN106793970B (zh) 用于诊断及治疗的纳米载剂及其加工
Agrahari et al. Nanocarrier fabrication and macromolecule drug delivery: challenges and opportunities
JP6507102B2 (ja) 薬物送達キャリアとしての生分解性でかつ臨床上適合性のナノ粒子
McMasters et al. Delivery of anti-inflammatory peptides from hollow PEGylated poly (NIPAM) nanoparticles reduces inflammation in an ex vivo osteoarthritis model
Li et al. Multiple delivery strategies of nanocarriers for myocardial ischemia-reperfusion injury: current strategies and future prospective
US11850309B2 (en) Cationic materials and formulations for drug delivery
Xie et al. A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer
Pascual-Gil et al. Tracking the in vivo release of bioactive NRG from PLGA and PEG–PLGA microparticles in infarcted hearts
Shi et al. Advances in nanotherapy for targeting senescent cells
JP2019537600A (ja) ポリマーナノ粒子
Yan et al. Elaboration a ROS-responsive darutigenol prodrug nanoassemblies for inflammatory arthritis treatment
CN107157950A (zh) 一种白蛋白纳米粒及其制备方法和用途
Zhang et al. Development and advantages of drug delivery systems
Huang et al. Neutrophil-targeted nanomedicine delivery systems: therapeutic applications and future perspectives in sepsis management
Adnan et al. Peptide-Based Nanocarriers for Targeted Drug Delivery: Recent Advances, Strategies, and Therapeutic Frontiers
CN111107842B (zh) 利用微混合和卡培他滨两亲性特性的卡培他滨的聚合物-脂质混杂纳米颗粒
US10632080B2 (en) Compositions and methods to improve nanoparticle distribution within the brain interstitium
Qaiser et al. Nanotechnology: a new hope for the cure of osteoarthritis, osteoporosis and rheumatoid arthritis
WO2014044894A1 (es) Formulación de liberación controlada
WO2012094512A2 (en) Myocardial tissue targeting peptides
Gohil et al. Nanocarriers in protein and peptide drug delivery
CHEN et al. Cartilage targeting function in the drug delivery system by intra-articular injection for the treatment of osteoarthritis
US12465569B2 (en) Microparticle formulations for intravenous therapy and methods for their manufacture and use

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20181126